Skip to main content
SpringerLink
Log in

Intraperitoneal Chemotherapy and Immunotherapy

  • Conference paper
Combined Modality Therapy of Gastrointestinal Tract Cancer

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 110))

Abstract

Treatment failures following putatively curative resections for circumscribed neoplasms are well recognized and the recurrence patterns have been analyzed. These observations compel us to reshape our conceptual model, for such cancers, from one of malignancy as a localized process to that of a regionalized process. Consequently, treatments should evolve to include not only the primary cancer (removedby surgery) but also the entire anatomic region (peritoneal cavity). Regionalized processes command a combined-modality approach to effect cure or, at least, to favorably alter the natural history of the disease. It follows, then, that if for a given neoplasm the available agents are not ideal and, furthermore, that no new agents have been developed in the recent past that offer a hope of improved survival ; we must exploit the agents at hand in the most effective manner.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Clarkson B, O’Connor A, Wilson L et al. (1964) The physiologic disposition of 5-fluo-rouracil and 5-fluoro-2(l)-deoxyuridine in man. Clin Pharmacol Ther 5: 581–610

    PubMed  CAS  Google Scholar 

  2. Chabner BA, Young RC (1973) Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest 52: 1804–1811

    Article  PubMed  CAS  Google Scholar 

  3. Myers CE, Collins JM (1983) Pharmacology of intraperitoneal chemotherapy. Cancer Invest 1 (5): 395–407

    Article  Google Scholar 

  4. Dedrick RL, Myers CE, Bungay PM, DeVita VT (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62: 1–11

    PubMed  CAS  Google Scholar 

  5. Flessner MF, Dedrick RL, Schulte JS (1984) A distributed model of periotoneal plasma transport: theoretical considerations. Am J Physiol 246: R597–R607

    PubMed  CAS  Google Scholar 

  6. Flessner MF, Fenstermacher JD, Blasberg RG, Dedrick RL (1985) Peritoneal absorption of macromolecules studied by quantitative autogradiography. Am J Physiol 248: H26–H32

    PubMed  CAS  Google Scholar 

  7. Flessner MF, Fenstermacher JD, Blasberg RG (1985) A distributed model of peritoneal-plasma transport: tissue concentration gradients. Am J Physiol 248: F425–F435

    PubMed  CAS  Google Scholar 

  8. Flessner MF, Dedrick RL, Schulte JS (1985) A distributed model of peritoneal-plasma transport: analysis of experimental data in the rat. Am J Physiol 248: F413–F424

    PubMed  CAS  Google Scholar 

  9. Flessner MF, Dedrick RL, Schltz JS (1985) Exchange of macromolecules between peritoneal cavity and plasma. Am J Physiol: H15–H25

    Google Scholar 

  10. Dedrick RL (1985) Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 12(3): 1–6

    PubMed  CAS  Google Scholar 

  11. Speyer JL, Sugarbaker PH, Collin JM, Dedrick RL, Kleeker RW, Meyers CE (1981) Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 41: pp 1916–1922

    PubMed  CAS  Google Scholar 

  12. Sugarbaker PH, Gianola FJ, Speyer JL, Wesley R, Barofsky I, Meyers CE (1985) Prospective randomized trial of intravenous v intraperitoneal 5-FU in patients with a primary colon or rectal cancer. Semin Oncol 12(3): 101–111

    PubMed  CAS  Google Scholar 

  13. Dedrick RL, Flessner MF, Collins JM et al. (1982) Is the peritoneum a membrane? ASAIO 5(1): 1–8

    Google Scholar 

  14. Dunnick NR, Jones RB, Doppman JL, Speyer J, Myers CE (1979) Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics. AJR 133: 221–223

    PubMed  CAS  Google Scholar 

  15. Feldman GB, Knapp RI (1974) Lymphatic drainage of the peritoneal cavity and its significance in ovarian cancer. Am J Obstet Gynecol. 119: 991–994

    PubMed  CAS  Google Scholar 

  16. Leichner PT, Rosenshein NB, Leibel SA et al. (1980) Distribution and tissue dose of in-traperitoneally administered radioactive chromic phosphate in New Zealand white rabbits. Radiology 134: 729–734

    PubMed  CAS  Google Scholar 

  17. Rosenshein N, Blake D, McIntyre P et al. (1978) The effect of volume on the distribution of substances instilled into the peritoneal cavity. Gynecol Oncol 6: 106–110

    Article  PubMed  CAS  Google Scholar 

  18. Teckhoff H, Schecter H (1968) A bacteriologically safe peritoneal access device. ASAO 12:181

    Google Scholar 

  19. Tenckhoff H (1974) Manual for chronic peritoneal dialysis. University of Washington School of Medicine, Seattle

    Google Scholar 

  20. Twardowski ZJ (1985) Intraperitoneal therapy in renal failure. Semin Oncol 12(3): 81–89

    PubMed  CAS  Google Scholar 

  21. Piccart M J, Speyer JL, Markman M, ten Bokkel-Huinink WW, Alberts D, Jenkins J, Muggia F (1985) Intraperitoneal chemotherapy: technical experience at five institutions. Semin Oncol 12(3): 90–96

    PubMed  CAS  Google Scholar 

  22. Jenkins J, Sugarbaker PH, Gianola FJ, Myers CE (1982) Technical considerations in the use of intraperitoneal chemotherapy administered by Tenckhoff catheter. Surg Gynecol Obstet 154: 858–864

    PubMed  CAS  Google Scholar 

  23. Jenkins J (1983) Managing intraperitoneal chemotherapy: a medical, nursing and personal challenge. Semin Oncol 12(3): 97–100

    Google Scholar 

  24. Davis AS, Reed WP (1983) A leak-free technique for open insertion of peritoneal dialysis catheters. Surg Gynecol Obstet 157: 579–580

    PubMed  CAS  Google Scholar 

  25. Cerilli J, Walker J, Bay W (1983) A new technique for placement of catheters for peritoneal dialysis. Sur Gynecol Obstet 156: 663–664

    CAS  Google Scholar 

  26. Ozols RF, Myers CE, Young RC (1984) Intraperitoneal chemotherapy. Ann Intern Med 100: 1 118–120

    Google Scholar 

  27. Longo DL, Young RC (1981) The natural history and treatment of ovarian cancer. Annu Rev Med 32: 475–490

    Article  PubMed  CAS  Google Scholar 

  28. Buchsbaum HJ, Lifshitz S (1984) Staging and surgical evaluation of ovarian cancer. Semin Oncol 11(3): 227–237

    PubMed  CAS  Google Scholar 

  29. Kavanagh JJ (1985) Investigational therapies for epithelial ovarian cancer. Clin Obstet Gynec 28(4): 846–852

    Article  PubMed  CAS  Google Scholar 

  30. Young RC (1984) Ovarian cancer treatment: progress of paralysis? Semin Oncol 11(3): 327–329

    PubMed  CAS  Google Scholar 

  31. Ozols RF, Young RC (1984) Chemotherapy of ovarian cancer. Semin Oncol 11(3): 251–263

    PubMed  CAS  Google Scholar 

  32. Thigpen JT, Vance RB, Lodovico B, Khansur TF (1984) New drugs and experimental approaches in ovarian cancer treatment. Semin Oncol 11(3): 314–326

    PubMed  CAS  Google Scholar 

  33. Hamilton TC, Young RC, Ozols RF (1984) Experimental model systems of ovarian cancer: applications to the design and evaluation of new teatment approaches. Semin Oncol 11(3): 285–298

    PubMed  CAS  Google Scholar 

  34. Ozols R (1985) Intraperitoneal chemotherapy in the management of ovarian cancer. Semin Oncol 12(3): 75–80

    PubMed  CAS  Google Scholar 

  35. Cohen CJ (1985) Surgical considerations in ovarian cancer. Semin Oncol 12(3): 53–56

    PubMed  CAS  Google Scholar 

  36. Thigpen T, Blessing JA (1985) Current therapy of ovarian carcinoma: an overview. Semin Oncol 12(3): 47–52

    PubMed  CAS  Google Scholar 

  37. Alberts DS, Young L, Mason N, Salmon SE (1985) In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 12(3): 38

    PubMed  CAS  Google Scholar 

  38. Tong D, Russell AH, Dawson Le et al. (1983) Second laparotomy for proximal colon cancer. Am J Surg 145: 382–386

    Article  PubMed  CAS  Google Scholar 

  39. Speyer JL (1985) The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies. Semin Oncol 12(3): 23–28

    PubMed  CAS  Google Scholar 

  40. Douglass HO (1985) Gastric cancer: overview of current therapies. Semin Oncol 12(3): 57–62

    PubMed  Google Scholar 

  41. Wilson RE (1985) Surgical considerations in gastric cancer. Semin Oncol 12(3): 63–68

    PubMed  CAS  Google Scholar 

  42. Brenner DE (1986) Intraperitoneal chemotherapy: a review. J Clin Oncol 4(7): 1135–1147

    PubMed  CAS  Google Scholar 

  43. Higgins GA Jr, Lyndon EL, Dwight RW, Keeher RJ (1978) The case of adjuvant 5-fluo-rouracil in colorectal cancer. Cancer Clin Trials, Spring: 35–41

    Google Scholar 

  44. Christophidis N, Vajda FJE, Lucas I, Drummer O, Moon WJ, Lornis WJ (1978) Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokin 3: 33–336

    Article  Google Scholar 

  45. deBruijn EA, VanOosterom AT, Tjaden UR, Recuwijk HJEM, Pinedo HM (1985) Pharmacology of 5-deoxy-5-fluorouridine in patients with resistant ovarian cancer. Cancer Res 45: 5931–5935

    PubMed  Google Scholar 

  46. Speyer JL, Collins JM, Dedrick RL, Brennan MF, Buckpitt AR, Londer H, DeVita VT, Myers CE (1980) Phase-I and pharmacological studies of 5-fluorouracil administration intraperitoneally. Cancer Res 40: 567–572

    PubMed  CAS  Google Scholar 

  47. Jones RB, Collins JM, Myers CE, Brooks AE, Hubbard SM, Balow JE, Brennan MF, Dedrick RL, DeVita VT (1981) High-volume intraperitoneal chemotherapy with method-trexate in patients with cancer. Cancer Res 41: 55–59

    PubMed  CAS  Google Scholar 

  48. Howel SB, Chu BB, Wung WE et al. (1981) Long-duration intracavitary infusion of methotrexate with systemic Leucovorin protection in patients with malignant effusions. J Clin Invest 67: 1161–1170

    Article  Google Scholar 

  49. Howell SB (1985) Intraperitoneal chemotherapy: the use of concurrent systemic neutralizing agents. Semin Oncol 12(3): 17–22

    PubMed  CAS  Google Scholar 

  50. Ozols RF, Young RC (1985) High-dose cisplatin therapy in ovarian cancer. Semin Oncol 12(4): 21–30

    PubMed  CAS  Google Scholar 

  51. Lopez JA, KrisKorian JG, Reich SD, Smyth RD, Lee FH, Isseil BF (1985) Clinical pharmacology of intraperitoneal cisplatin. Gynecol ncol 20: 1–9

    Article  CAS  Google Scholar 

  52. Makman M, Cleary S, Howells SB (1985) Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection. Eur J Cancer Clin Oncol 21 (9): 1015–1018

    Article  Google Scholar 

  53. Howell SB, Pfeifle CE, Wung WE, Olshen RA (1983) Intraperitoneal cis-diamminedich-loroplatinum with system thiosulfate protection. Cancer Res 43: 1426–1431

    PubMed  CAS  Google Scholar 

  54. ten Bokkel-Huinink WW, Bubbelman R, Aartsen E, Franklin H, McVie JG (1985) Experimental and clinical results with intraperitoneal cisplatin. Semin Oncol 12(3): 43–46

    PubMed  Google Scholar 

  55. Pretonius RG, Hacker NF, Berek JS, Ford LC, Hoeschele JD, Butler TA, LaGasse LD (1983) Pharmacokinetics of i.p. cisplatin in refractory ovarian carcinoma. Cancer Treat Rep 67(12): 1085–1092

    Google Scholar 

  56. Ozols RF, Young RC, Speyer JL et al. (1982) Phase-I and pharmacologic studies of adri-amycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 42: 4265–4269

    PubMed  CAS  Google Scholar 

  57. Howell SB, Pfeifle CE, Olshen, RA (1984) Intraperitoneal chemotherapy with melphal-an. Ann Int Med 101: 14–18

    PubMed  CAS  Google Scholar 

  58. Holcenberg J, Anderson T, Ritch P et al. (1983) Intraperitoneal chemotherapy with mel-phalan plus glutaminase. Cancer Res 43: 1381–1388

    PubMed  CAS  Google Scholar 

  59. King ME, Pfeifle CE, Howell SB (1984) Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma. J Clin Oncol 2: 662–669

    PubMed  CAS  Google Scholar 

  60. Markman M, Cleary S, Lucas WE, Howell SB (1985) Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarianm carcinoma and other malignancies principally involving the peritoneal cavity. J Clin Oncol 3: 7

    Google Scholar 

  61. Markman M (1985) Melphalan and cytarabine administered intraperitonealy as single agents and combination intraperitoneal chemotherapy with cisplatin and cytarabine. Semin Oncol 12(3): 33–37

    PubMed  CAS  Google Scholar 

  62. Weiss G, Von Hoff DD (1985) Human tumor cloning assay: clinical applications for ovarian, gastric, pancreatic and colorectal cancers. Semin Oncol 12(3): 69–74

    PubMed  CAS  Google Scholar 

  63. Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RB, Brady J, Greene T, Ettinger LM, Lagasse LD, Bonnern EM, Spiegel RJ, Zigheboim J (1985) Intraperitoneal recombinant a-interferon for “salvage” immunotherapy in stage-III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Cancer Res 45: 4447–4453

    PubMed  CAS  Google Scholar 

  64. Lotze MT, Custer MC, Rosenberg SA (1987) Intraperitoneal administration of interleu-kin-2 in patients with cancer. Arch Surg (in press)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Health Science Center, University School of Medicine, 1327 Clifton Road N.E., Atlanta, GA, 30322, USA

    B. E. Wolf & P. H. Sugarbaker

Authors
  1. B. E. Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. H. Sugarbaker
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Chirurgische Klinik, Klinikum der Universität Heidelberg, Im Neuenheimer Feld 110, 6900, Heidelberg, Germany

    Peter Schlag  & Peter Hohenberger  & 

  2. Departement Chirurgie, Universitätsspital Zürich, Rämistraße 100, 8091, Zürich, Switzerland

    Urs Metzger

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Wolf, B.E., Sugarbaker, P.H. (1988). Intraperitoneal Chemotherapy and Immunotherapy. In: Schlag, P., Hohenberger, P., Metzger, U. (eds) Combined Modality Therapy of Gastrointestinal Tract Cancer. Recent Results in Cancer Research, vol 110. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83293-2_37

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-83293-2_37

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-83295-6

  • Online ISBN: 978-3-642-83293-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation